Mirum Pharmaceuticals Inc

For the period ended Jun 30, 2024. Filed Aug 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 7, 2024

MIRM$94.42+1.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)

	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023
Revenue:
Product sales, net	$77,760	$32,497	$146,677	$61,595
License and other revenue	115	5,000	420	7,500
Total revenue	77,875	37,497	147,097	69,095
Operating expenses:
Cost of sales	20,227	6,812	38,057	11,791
Research and development	32,672	22,009	64,894	45,557
Selling, general and administrative	49,208	32,949	94,846	63,168
Total operating expenses	102,107	61,770	197,797	120,516
Loss from operations	(24,232)	(24,273)	(50,700)	(51,421)
Other income (expense):
Interest income	3,486	3,627	7,119	5,899
Interest expense	(3,569)	(3,726)	(7,146)	(7,968)
Loss from termination of revenue interest purchase agreement	—	(49,076)	—	(49,076)
Other income (expense), net	312	(274)	2,069	(1,085)
Net loss before provision for income taxes	(24,003)	(73,722)	(48,658)	(103,651)
Provision for income taxes	635	316	1,259	517
Net loss	$(24,638)	$(74,038)	$(49,917)	$(104,168)
Net loss per share, basic and diluted	$(0.52)	$(1.94)	$(1.06)	$(2.75)
Weighted-average shares of common stock outstanding, basic and diluted	47,235,080	38,107,334	47,081,315	37,892,513

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.